Nexentis Technologies Inc. (NXTS) Stock Price & Analysis

Nexentis Technologies Inc. (NXTS) fell 5.76% to USD 1.8 as of July 25, 2026 at 05:04 UTC, according to Nexqual real-time market data.

NXTS last closed at USD 1.91; the session ranged USD 1.76–1.94 on volume of 18,561 shares. Market capitalization is $2.62M, with a 52-week range of USD 1.76–82.32 (NCM). Source: Nexqual, July 25, 2026 at 05:04 UTC.

Key Statistics (as of July 25, 2026 at 05:04 UTC)

Technical Analysis (NXTS)

Nexqual's technical model rates NXTS "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 05:04 UTC.

Analyst Ratings (NXTS)

Wall Street analysts rate NXTS "None", per Nexqual as of July 25, 2026 at 05:04 UTC.

Earnings (NXTS)

Source: Nexqual, July 25, 2026 at 05:04 UTC.

Financials & Fundamentals (NXTS)

Source: Nexqual, July 25, 2026 at 05:04 UTC.

Financial Health Score (NXTS)

Nexqual rates Nexentis Technologies Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 05:04 UTC.

Ownership (NXTS)

Source: Nexqual, July 25, 2026 at 05:04 UTC.

Leadership (NXTS)

Nexentis Technologies Inc. is led by David Palach (age 59), Chief Executive Officer, per Nexqual as of July 25, 2026 at 05:04 UTC.

Major Backers & Investors (NXTS)

Notable institutional backers of Nexentis Technologies Inc. include Fidelity, Xtx Topco Ltd, Yorkville Advisors Global, LP, according to Nexqual as of July 25, 2026 at 05:04 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, July 25, 2026 at 05:04 UTC.

From Nexentis Technologies Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)

Key Strengths & Strategy (as disclosed to the SEC)

• MitoCareX currently has an application for registration of "MITOLINE™" mark in the United States.   Scope and Duration of Intellectual Property Protection   The area of patents and other intellectual property rights in the biopharmaceutical industry is an evolving one with many risks and uncertainties, and third parties may have blocking patents that could be used to prevent us from commercializing our product candidates and practicing our proprietary technology.
• For this and other risks related to our proprietary technology, inventions, improvements, and product candidates.   We also rely on trade secret protection for our confidential and proprietary information.
• The solutions are based on our proprietary blend of food acids combined with certain types of oxidizing agent-based sanitizers and in some cases with fungicides at low concentrations.
• These limitations have pushed MitoCareX to develop MITOLINE™ – a novel proprietary algorithm which outputs can be used for the generation of reliable 3D models for potentially all the 53 human mitochondrial proteins.   Mitochondrial carriers are directly linked to diverse types of malignancies (PMID 32783608) including lung cancer – the 2nd worldwide cancer in the world.

Partnerships

• By forming a temporary protective shield around the fresh produce we treat, our solutions make it difficult for pathogens to develop and potentially provide protection which also reduces cross-contamination.   On January 13, 2026, we entered into the SF Agreement with Voice Assist, and, for certain limited purposes set forth therein, Save Foods.
• Brand is a private company wholly owned by Brand (M.G.) Ltd., (a public company).   In Poland and Italy, Solterra Energy operates through Solterra in collaboration with Brand.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 05:04 UTC. This page is informational and not investment advice.